Takeda Pharmaceutical Company Limited (TKDA) — Cash Flow Reinvestment Rate
Takeda Pharmaceutical Company Limited (TKDA) has a Cash Flow Reinvestment Rate of 0.63x as of December 2025, reinvesting €235.74 Billion (capex €222.37 Billion plus investments €-13.37 Billion) from operating cash flow of €373.25 Billion. Check Takeda Pharmaceutical Company Limited cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Takeda Pharmaceutical Company Limited Cash Flow Reinvestment Rate (2017–2025)
Historical reinvestment intensity for Takeda Pharmaceutical Company Limited across 9 annual periods. Explore TKDA long-term investments to assets to see how much of total assets are deployed in long-term investments.
Annual Cash Flow Reinvestment Rate for Takeda Pharmaceutical Company Limited (2017–2025)
Year-by-year capital reinvestment analysis for Takeda Pharmaceutical Company Limited. For live market cap and broader valuation context, see TKDA stock market capitalisation.
| Year | Reinvestment Rate | Total Reinvested (EUR) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.44x | €461.57 Billion | €1.06 Trillion | €379.62 Billion | ▼ -66.9% |
| 2024 | 1.32x | €944.59 Billion | €716.34 Billion | €480.73 Billion | ▲ +3.8% |
| 2023 | 1.27x | €1.24 Trillion | €977.16 Billion | €633.69 Billion | ▲ +981.8% |
| 2022 | 0.12x | €131.83 Billion | €1.12 Trillion | €123.25 Billion | ▼ -31.5% |
| 2021 | 0.17x | €173.21 Billion | €1.01 Trillion | €111.21 Billion | ▼ -32.1% |
| 2020 | 0.25x | €168.93 Billion | €669.75 Billion | €127.08 Billion | ▼ -34.0% |
| 2019 | 0.38x | €125.61 Billion | €328.48 Billion | €77.68 Billion | ▲ +59.0% |
| 2018 | 0.24x | €90.86 Billion | €377.85 Billion | €67.00 Billion | ▼ -8.2% |
| 2017 | 0.26x | €68.50 Billion | €261.36 Billion | €61.66 Billion | — |